Reuters logo
BRIEF-Astrazeneca presents new data underpinning safety profile and real-world cv outcomes of Farxiga at ADA 2017
June 12, 2017 / 11:03 AM / 3 months ago

BRIEF-Astrazeneca presents new data underpinning safety profile and real-world cv outcomes of Farxiga at ADA 2017

June 12 (Reuters) - Astrazeneca Plc

* Astrazeneca presents new data underpinning safety profile and real-world cv outcomes of farxiga at ada 2017

* Astrazeneca Plc -comprehensive updated analysis provides evidence on safety profile of farxiga, including no imbalance in lower-limb amputations

* Says new analyses from cvd-real examine reductions in cv events for sglt-2 inhibitors

* Astrazeneca - in an updated safety analysis, data pooled from 30 phase iib/iii clinical trials for dapagliflozin showed no new safety signals

* Astrazeneca - data from 30 phase iib/iii clinical trials for dapagliflozin showed incidence of adverse events generally similar to that in control groups Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below